Edition:
United Kingdom

MiMedx Group Inc (MDXG.OQ)

MDXG.OQ on NASDAQ Stock Exchange Capital Market

7.34USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$7.34
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
857,680
52-wk High
$18.24
52-wk Low
$6.05

Select another date:

Wed, Mar 28 2018

BRIEF-MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of Amniofix® Injectable For Treatment Of Osteoarthritis Of The Knee

* MIMEDX ENROLLS FIRST PATIENT IN ITS PHASE 2B CLINICAL TRIAL OF RMAT DESIGNATED AMNIOFIX® INJECTABLE FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage:

BRIEF-Mimedx Reports Positive Results From Phase 2B Clinical Trial Of Amniofix Injectable

* MIMEDX REPORTS POSITIVE PAIN AND FOOT FUNCTION RESULTS FROM PHASE 2B CLINICAL TRIAL OF AMNIOFIX® INJECTABLE IN THE TREATMENT OF PLANTAR FASCIITIS

BRIEF-MiMedx Says "Confident" in Q1 Rev Guidance, Discloses DoJ Investigation

* MIMEDX ANNOUNCES EXPECTATION TO EXCEED THE $92 MILLION TOP END OF FIRST QUARTER REVENUE GUIDANCE

BRIEF-Mimedx's Amniofix Injectable Granted RMAT Designation By FDA

* AMNIOFIX INJECTABLE GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION BY THE FDA FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE

BRIEF-Mimedx Group Files For Non-Timely 10-K - SEC Filing

* MIMEDX - NOT ABLE TO PROVIDE QUANTITATIVE DESCRIPTION OF CHANGES IN RESULTS BETWEEN 2017, PRIOR PERIODS UNTIL AUDIT COMMITTEE COMPLETES INVESTIGATION Source text (http://bit.ly/2t9DPzh) Further company coverage: (Reuters.Brief@thomsonreuters.com)

U.S. Justice Department probing MiMedx's business practices: Bloomberg

Regenerative medicine maker MiMedx Group Inc is under federal investigation related to two business practices, Bloomberg reported on Monday, citing people familiar with the matter.

U.S. Justice Dept probing MiMedx's business practices - Bloomberg

Feb 26 Regenerative medicine maker MiMedx Group Inc is under federal investigation related to two business practices, Bloomberg reported on Monday, citing people familiar with the matter.

BRIEF-Mimedx Comments On Magistrate Recommendation In Co's Lawsuit Against Short Sellers

* MIMEDX COMMENTS ON MAGISTRATE RECOMMENDATION IN THE COMPANY'S LAWSUIT AGAINST SHORT SELLERS

BRIEF-Mimedx Announces First Patients Have Been Enrolled In The Phase 3 Clinical Trial Of Amniofix

* MIMEDX ANNOUNCES FIRST PATIENTS HAVE BEEN ENROLLED IN THE PHASE 3 CLINICAL TRIAL OF AMNIOFIX® INJECTABLE IN PATIENTS WITH RECALCITRANT PLANTAR FASCIITIS PAIN

BRIEF-Mimedx Settles Patent Infringement Lawsuit

* MIMEDX - SUCCESSFULLY SETTLED CO'S PATENT INFRINGEMENT LAWSUIT AGAINST MUSCULOSKELETAL TRANSPLANT FOUNDATION, MEDLINE INDUSTRIES, LIVENTA BIOSCIENCE

Select another date: